TY - JOUR
T1 - The effect of calcium channel blockers on the outcome of acute myeloid leukemia
AU - Chae, Young Kwang
AU - Dimou, Anastasios
AU - Pierce, Sherry
AU - Kantarjian, Hagop
AU - Andreeff, Michael
N1 - Funding Information:
This study was supported by a grant from the ASCO Young Investigator Award (to Y.K.C.) and, in part, supported by funding from the National Cancer Institute (CA55164, CA100632) and the Haas Chair in Genetics (to M.A.).
Publisher Copyright:
© 2014 Informa UK, Ltd.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - The effect of calcium channel blockers (CCBs), beta blockers and angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) on the prognosis of patients with acute myeloid leukemia (AML) is largely unknown. We collected data on the use of these medications in 1043 patients with AML, excluding promyelocytic leukemia, diagnosed and treated at M. D. Anderson Cancer Center between 2000 and 2012. Treatment with either amlodipine or diltiazem predicted a worse overall survival (hazard ratio [HR] 1.6, 95% confidence interval [CI] 1.22-2.06, p < 0.0001). There was no difference in survival depending on whether patients were taking beta blockers, ACE inhibitors or ARBs. The effect of CCBs on survival was independent from the National Comprehensive Cancer Network risk classification, age, performance status, response to treatment, year of diagnosis and CD34 levels, assessed by flow cytometry (HR 1.39, 95% CI 1.05-1.80, p = 0.02). Treatment with either amlodipine or diltiazem predicts worse survival in patients with AML independent of known prognostic factors.
AB - The effect of calcium channel blockers (CCBs), beta blockers and angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) on the prognosis of patients with acute myeloid leukemia (AML) is largely unknown. We collected data on the use of these medications in 1043 patients with AML, excluding promyelocytic leukemia, diagnosed and treated at M. D. Anderson Cancer Center between 2000 and 2012. Treatment with either amlodipine or diltiazem predicted a worse overall survival (hazard ratio [HR] 1.6, 95% confidence interval [CI] 1.22-2.06, p < 0.0001). There was no difference in survival depending on whether patients were taking beta blockers, ACE inhibitors or ARBs. The effect of CCBs on survival was independent from the National Comprehensive Cancer Network risk classification, age, performance status, response to treatment, year of diagnosis and CD34 levels, assessed by flow cytometry (HR 1.39, 95% CI 1.05-1.80, p = 0.02). Treatment with either amlodipine or diltiazem predicts worse survival in patients with AML independent of known prognostic factors.
KW - Acute myeloid leukemia
KW - Amlodipine
KW - Angiotensin receptor blockers
KW - Angiotensin-converting enzyme inhibitors
KW - Beta blockers
KW - Calcium channel blockers
KW - Diltiazem
UR - http://www.scopus.com/inward/record.url?scp=84919448485&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84919448485&partnerID=8YFLogxK
U2 - 10.3109/10428194.2014.901513
DO - 10.3109/10428194.2014.901513
M3 - Article
C2 - 24628293
AN - SCOPUS:84919448485
SN - 1042-8194
VL - 55
SP - 2822
EP - 2829
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 12
ER -
